Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
Status:
Terminated
Trial end date:
2018-02-21
Target enrollment:
Participant gender:
Summary
The combination of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) may be better than
other combinations used to treat earlier stage pancreatic cancer patients with resectable
(able to be cut out), borderline resectable, and locally advanced pancreatic adenocarcinoma.
For subjects who can not obtain Capecitabine can be treated with 5-Fluorouracil (5-FU) along
with Oxaliplatin and Irinotecan. Though all of the drugs in this study have been approved by
the FDA, their combination is investigational. The purpose of this study is to evaluate the
effects of CAPOXIRI (good and bad) on you and your cancer.